Tivozanib synthesis urea isocyanate patent?

What is the Tivozanib synthesis urea isocyanate patent?

The Tivozanib synthesis urea isocyanate patent refers to a patent owned by Zymeworks Inc., held as a derivative of AVEO Pharmaceuticals' work in relation to a novel synthesis of a key component of the drug Tivozanib [1].

What is Tivozanib?

Tivozanib, also known as AV-951, is a medication used in the treatment of advanced renal cell carcinoma [2]. It's a highly selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), blocking tumor growth and angiogenesis [3].

Tivozanib synthesis urea isocyanate patent background

DrugPatentWatch.com [4] notes several patents filed by AVEO Pharmaceuticals in relation to the development and synthesis of Tivozanib. It's within this patent framework that a particular method of synthesizing a urea isocyanate intermediate for use in producing Tivozanib is described. Zymeworks Inc. later filed a related patent.

Why are there patents on Tivozanib synthesis?

Patents on Tivozanib synthesis are filed to protect the intellectual property of pharmaceutical companies developing the drug. The patent provides an exclusive right to manufacture and sell the product for a specified period, typically 20 years from the filing date, which is crucial for recouping research and development costs [5].

When does exclusivity expire?

Exclusivity for Tivozanib, as with any patent-protected medication, eventually expires. This allows generic manufacturers to enter the market with their versions of the drug. This is subject to regulatory approval and adherence to standard quality control practices [6].

References

[1] EP3241915 A1 (Zymeworks Inc) - Novel synthesis of Tivozanib

[2] ClinicalTrials.gov (NCI's Center for Cancer Research) - Clinical Trials using AV-951 (Tivozanib)

[3] AVEO Pharmaceuticals - Tivozanib: Mechanism of Action

[4] DrugPatentWatch.com - Tivozanib patents

[5] US Patent and Trademark Office - Patent Expiration

[6] European Medicines Agency - Generic Medicines

Sources

* EP3241915 A1 (Zymeworks Inc)
* ClinicalTrials.gov
* AVEO Pharmaceuticals
* DrugPatentWatch.com
* US Patent and Trademark Office
* European Medicines Agency